SEC Form 4 · accession 0000899243-17-018008

AILERON THERAPEUTICS INC · ALRN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

10% Owner

Period of report

Jul 5, 2017

Accepted (ET)

Jul 6, 2017 · 6:14 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001420565

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Jul 5, 2017	C	144,773	—	A	144,773	I	See footnote
Common Stock^F2	Jul 5, 2017	P	33,333	$15.00	A	178,106	I	See footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series D Preferred Stock^F2,F1	—	Jul 5, 2017	C	847,721	D	—	—	Common Stock	85,309	I
Series E-2 Preferred Stock^F2,F1	—	Jul 5, 2017	C	183,944	D	—	—	Common Stock	18,511	I
Series E-3 Preferred Stock^F2,F1	—	Jul 5, 2017	C	159,548	D	—	—	Common Stock	16,055	I
Series F Preferred Stock^F2,F1	—	Jul 5, 2017	C	247,398	D	—	—	Common Stock	24,896	I

F1The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F2These shares are held by the Muneer A. Satter Revocable Trust and various other trusts and entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares.